Vinge has advised CELLINK AB (publ) in connection with the acquisition of all shares in Ginolis Oy. Ginolis conducts operations in relation to automated diagnostics and provides advanced robotic solutions to the medical- and diagnostics industries.
Vinge advises Atlas Antibodies AB (majority owned by Patricia Industries, a part of Investor AB), in connection with its acquisition of HistoCyte Laboratories Ltd.
The recapitalisation is carried out to strengthen ITAB’s capital structure to reduce the financial leverage of the group, to invest in the One ITAB transformation plan and to provide sufficient headroom to the business given the Covid-19 situation.
Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore Pharma receives gross proceeds of SEK 336 million.
Vinge advises BHG Group AB (publ) in connection with a directed share issue of approximately SEK 1.6 billion through an accelerated book building procedure, and a coordinated sale of approximately 1.2 million shares as part of the company’s incentive program.
Vinge has advised EQT in connection with the signing of a combination with Exeter Property Group, a global leading real estate investment manager with more than $ 10 billion of assets under management. The total consideration amounts to MUSD 1,870.
VGC Partners I LP (”VGC”) has invested MSEK 52.5 in a directed share issue in Sproud International AB ("Sproud"), in order to finance Sproud’s continued expansion of its range of sustainable pea-based products under the trademark Sproud, as an alternative to dairy products.
Vinge has advised Fastighets AB Trianon (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm’s main market.
Vinge has advised Fortinova Fastigheter AB (publ) (“Fortinova”) in connection with its listing on Nasdaq First North Premier Growth Market (“Nasdaq First North Premier”). The prospectus was published on 6 November 2020 and the trading on Nasdaq First North Premier commenced on 19 August 2020.
Roar BidCo AB has announced a public offer to the shareholders and holders of convertible bonds of Recipharm AB (publ). The offer values all outstanding shares and convertible bonds in Recipharm at approx. SEK 23.6 billion.
Latour Industries AB has announced a public offer to the shareholders of Allgon AB (publ). The offer values all outstanding shares in Allgon at approx. SEK 604 million.
Vinge is advising Medivir AB (publ) in connection with a rights issue which will provide Medivir with issue proceeds amounting to a maximum of SEK 170 million, as well as with an over-allotment option by way of a directed share issue of a maximum of approximately SEK 25 million.
